C
27.61
-1.26 (-4.36%)
| Previous Close | 28.87 |
| Open | 28.15 |
| Volume | 22,225 |
| Avg. Volume (3M) | 1,070,767 |
| Market Cap | 2,569,069,056 |
| Price / Sales | 2.70 |
| Price / Book | 2.44 |
| 52 Weeks Range | |
| Earnings Date | 7 May 2025 - 12 May 2025 |
| Operating Margin (TTM) | -32,613.47% |
| Diluted EPS (TTM) | -3.69 |
| Quarterly Revenue Growth (YOY) | -59.60% |
| Total Debt/Equity (MRQ) | 3.90% |
| Current Ratio (MRQ) | 23.05 |
| Operating Cash Flow (TTM) | -225.97 M |
| Levered Free Cash Flow (TTM) | -136.41 M |
| Return on Assets (TTM) | -20.46% |
| Return on Equity (TTM) | -32.02% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Crinetics Pharmaceuticals, Inc. | Bearish | Bullish |
AIStockmoo Score
1.3
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | 5.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | -0.5 |
| Average | 1.25 |
|
Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its products include Paltusotine and Atumelnant. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 2.05% |
| % Held by Institutions | 110.85% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Driehaus Capital Management Llc | 31 Dec 2024 | 6,141,014 |
| Ecor1 Capital, Llc | 31 Dec 2024 | 4,288,120 |
| Farallon Capital Management Llc | 31 Dec 2024 | 4,075,098 |
| Paradigm Biocapital Advisors Lp | 31 Dec 2024 | 1,910,761 |
| Siren, L.L.C. | 31 Dec 2024 | 1,609,652 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 91.00 (Citizens Capital Markets, 229.59%) | Buy |
| Median | 70.50 (155.34%) | |
| Low | 55.00 (Jefferies, 99.20%) | Buy |
| Average | 71.75 (159.87%) | |
| Total | 4 Buy | |
| Avg. Price @ Call | 37.12 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Stifel | 25 Mar 2025 | 60.00 (117.31%) | Buy | 35.07 |
| Citizens Capital Markets | 28 Feb 2025 | 91.00 (229.59%) | Buy | 35.78 |
| Jefferies | 22 Jan 2025 | 55.00 (99.20%) | Buy | 38.65 |
| HC Wainwright & Co. | 13 Jan 2025 | 81.00 (193.37%) | Buy | 38.98 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |